Shareholders Target Lilly Over Zyprexa

Law360, New York (April 4, 2007, 12:00 AM EDT) -- Eli Lilly and Co. has come under legal fire again over Zyprexa, this time from shareholders who claim the pharmaceutical giant engaged in an illicit scheme to conceal the side effects of its blockbuster anti-psychotic drug by marketing the medicine for off-label uses.

The lawsuit, filed March 28 in the U.S. District Court for the Eastern District of New York, accuses Lilly of misrepresenting Zyprexa’s known adverse side effects to investors.

The shareholders said in their complaint that Lilly knew of links between Zyprexa and extreme...
To view the full article, register now.